R&D Portfolio and Pipeline
AEF0117
for cannabis-related
disorders
AEF0117 has an open FDA’s IND and will enter phase IIb in the United States in 2021.
AEF0117 is a new molecular entity (NME) developed by Aelis Farma for the treatment of cannabis addiction, cannabis-induced Psychosis and Toxicity.
AEF0117 major characteristics:
Very high potency in inhibiting the effects of cannabis' active ingredient THC in several animal species including non-human primates without side effects on normal behavior.
Very favorable ADMET profile, with good oral absorption, brain access, long half-life and no toxic or adverse effects identified (Therapeutic index >14 000).
Excellent safety profile and PK characteristics in healthy volunteers and cannabis addicts.
The clinical development of AEF0117 is supported by the NIH (NIDA).
AEF0217
for cognitive
disorders
AEF0217 will enter phase I clinical trials in 2021 in Europe.
AEF0217 is the second NME developed by Aelis Farma. It is specifically tailored for the treatment of the cognitive deficits in Down syndrome and age-related cognitive impairment.
AEF0217 major characteristics:
Very high potency in reversing cognitive deficits in highly valid translational models of Down syndrome and subjective cognitive decline.
No behavioral side effects even in the fragile trisomic and aged mice.
Very favorable ADMET profile, with good oral absorption, brain access, long half-life and no toxic or adverse effect identified to date.
The clinical development of AEF0217 for Down syndrome is supported by the European Union (H2020).
New CB1-SSi
for other
cannabinoids-dependent
diseases
Aelis Farma’s screening platform provides a steady flow of new biased allosteric inhibitors of the CB1 receptor.
New CB1-SSi are NME with an original proprietary structure and improved pharmacodynamic properties providing follow-up for AEF0117 and AEF0217 and drug candidates for the treatment of other cannabinoids-dependent diseases which include several orphan diseases.